Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Current Assets: 2009-2024

Historic Current Assets for Ironwood Pharmaceuticals (IRWD) over the last 16 years, with Dec 2024 value amounting to $182.4 million.

  • Ironwood Pharmaceuticals' Current Assets rose 53.32% to $273.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $273.8 million, marking a year-over-year increase of 53.32%. This contributed to the annual value of $182.4 million for FY2024, which is 21.83% down from last year.
  • Ironwood Pharmaceuticals' Current Assets amounted to $182.4 million in FY2024, which was down 21.83% from $233.3 million recorded in FY2023.
  • In the past 5 years, Ironwood Pharmaceuticals' Current Assets registered a high of $780.6 million during FY2022, and its lowest value of $182.4 million during FY2024.
  • Its 3-year average for Current Assets is $398.8 million, with a median of $233.3 million in 2023.
  • As far as peak fluctuations go, Ironwood Pharmaceuticals' Current Assets spiked by 61.59% in 2020, and later tumbled by 70.12% in 2023.
  • Yearly analysis of 5 years shows Ironwood Pharmaceuticals' Current Assets stood at $495.8 million in 2020, then surged by 50.30% to $745.2 million in 2021, then increased by 4.75% to $780.6 million in 2022, then crashed by 70.12% to $233.3 million in 2023, then declined by 21.83% to $182.4 million in 2024.